secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2022-12-15T23:59:59+00:00
Accession:  0001193125-22-305886
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akebia CAO Violetta Cotreau to resign; CFO David Spellman named principal accounting officer
--------------------------------------------------------------------------------

- Violetta Cotreau resigns as Chief Accounting Officer, effective Dec 30, 2022, to pursue new career opportunity.
- David A. Spellman, currently CFO, appointed as principal accounting officer effective Dec 30, 2022.
- Spellman has over two decades of biopharma finance experience; previously at Vertex, Intarcia, and Mersana.
- Spellman will continue as CFO and Treasurer in addition to the principal accounting officer role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000119312522305886/0001193125-22-305886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000119312522305886/d412372d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-305886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer